HIGHLIGHTS
- who: BioMed Central and collaborators from the Address: IRCCS GGaslini, Genoa, Italy have published the research: Bio Med Central, in the Journal: (JOURNAL)
SUMMARY
A cross-sectional sample of 2,727 and 530 active JIA patients from the PRINTO methotrexate (MTX) trial, including those with at least 6/8 CHAQ functional areas, was analysed. The removal of aids/devices and/or help lead to a significant shift from severe to lower disability categories especially for patients in the active phase of disease. MTX trial patients had higher disease activity compared to the cross . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.